Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Bone Marrow Transplant. 2010 Dec 13;46(10):1382–1388. doi: 10.1038/bmt.2010.301

Table 1.

DLA-identical marrow transplantation after ECP± pentostatin and 100cGy TBI with postgrafting MMF and CSP1

Recipient Dog # Marrow TNCs × 108/kg Neutrophil Increase5 % Donor MNC Chimerism (Max-final) Rejection GVHD Duration of Chimerism (weeks)
Group 12 G347 5.5 Yes 37-0 Yes No 8
G406 2.1 Yes 40-0 Yes No 11
Group 23 G417 2.1 Yes 0-0 Yes No 0
G331 4.7 Yes 0-0 Yes No 0
G442 4.8 Yes 67-30 No No 31
Group 34 G449 3.2 Yes 34-0 Yes No 10
G472 2.6 Yes 22-0 Yes No 6
G342 5.9 Yes 0-0 Yes No 0
G5256 3.1 Yes 29-0 Yes No 7
1

Dog leukocyte antigen (DLA), total body irradiation (TBI) extracorporeal photophoresis (ECP), mycophenolate mofetil (MMF), and cyclosporine (CSP)

2

Dogs in Group 1 received ECP product on days -2 and -1; 100 cGy TBI on day 0; MMF (10 mg/kg twice daily subcutaneously) day 0 to day 27, and CSP (15 mg/kg twice daily orally on day -1 to day 35).

3

Dogs in Group 2 received ECP product on days -6 and -5; 4 mg/m2 pentostatin i.v. on days -4, -3, and -2; 100 cGy TBI on day 0; and same regimen of MMF and CSP as in group 1.

4

Dogs in Group 3 received ECP product on days -6 and -5; 4 mg/m2 pentostatin i.v. on days -14, -13, -12, -4, -3, and -2; 100 cGy TBI on day 0; and same regimen of MMF and CSP as in group 1.

5

Absolute neutrophil counts increase greater than 500/μL

6

G525 received ECP product on day -6 only due to machine malfunction.